Blogs

Robbins LLP Reminds Brainstorm Cell Therapeutics Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Against BCLI

Forex

<p>SAN DIEGO, Dec. 15, 2023 (GLOBE NEWSWIRE) &#8212; Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023. Brainstorm Cell is a biotechno

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Forex

<p>ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use ZORYVE foam provides rapid disease clearance and significant reduction in itch, one of the most burdensome symptoms of seborrheic derma

Page 1243 of 9786